






 Dolleman, M., Faddy, M.J., van Disseldorp, J., van der Schouw, Y.T., 
Messow, C.M., Leader, B., Peeters, P.H.M., McConnachie, A., Nelson, 
S.M., and Broekmans, F.J.M. (2013) The relationship between anti-
mullerian hormone in women receiving fertility assessments and age at 
menopause in subfertile women: evidence from large population studies. 




Copyright © 2013 The Endocrine Society 
 
A copy can be downloaded for personal non-commercial research or 
study, without prior permission or charge  
 
The content must not be changed in any way or reproduced in any format 
or medium without the formal permission of the copyright holder(s)  
 























Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
The Relationship Between Anti-Müllerian Hormone in
Women Receiving Fertility Assessments and Age at
Menopause in Subfertile Women: Evidence From
Large Population Studies
M. Dólleman,* M. J. Faddy, J. van Disseldorp, Y. T. van der Schouw,
C. M. Messow, B. Leader, P. H. M. Peeters, A. McConnachie, S. M. Nelson, and
F. J. M. Broekmans
Department of Reproductive Medicine and Gynaecology (M.D., J.v.D., F.J.M.B.), Julius Center for Health
Sciences and Primary Care (M.D., Y.T.v.d.S., P.H.M.P.), University Medical Centre Utrecht, 3508 GA
Utrecht, The Netherlands; School of Mathematical Sciences (M.J.F.), Queensland University of
Technology, 4001 Brisbane, Australia; School of Medicine (S.M.N.), University of Glasgow, Western
Infirmary, Glasgow G12 8QQ, United Kingdom; Clinical Research Division, ReproSource (B.L.), Inc,
Woburn, Massachusetts 01801; and Robertson Centre for Biostatistics (C.M.M., A.M.), University of
Glasgow, Glasgow G12 8QQ, United Kingdom
Context:Anti-Müllerian hormone (AMH) concentration reflects ovarian aging and is argued to be
a useful predictor of age at menopause (AMP). It is hypothesized that AMH falling below a critical
threshold corresponds to follicle depletion, which results in menopause. With this threshold, the-
oretical predictionsofAMPcanbemade.Comparisonsof suchpredictionswithobservedAMPfrom
population studies support the role for AMH as a forecaster of menopause.
Objective: The objective of the study was to investigate whether previous relationships between
AMH and AMP are valid using a much larger data set.
Setting: AMH was measured in 27 563 women attending fertility clinics.
Study Design: From these data a model of age-related AMH change was constructed using a
robust regression analysis. Data on AMP from subfertile women were obtained from the pop-
ulation-based Prospect-European Prospective Investigation into Cancer and Nutrition (Prospect-
EPIC) cohort (n  2249). By constructing a probability distribution of age at which AMH falls
below a critical threshold and fitting this to Prospect-EPIC menopausal age data using maximum
likelihood, such a threshold was estimated.
Main Outcome: The main outcome was conformity between observed and predicted AMP.
Results: To get a distribution of AMH-predicted AMP that fit the Prospect-EPIC data, we found the
critical AMH threshold should vary among women in such a way that women with low age-specific
AMHwould have lower thresholds, whereas women with high age-specific AMHwould have higher
thresholds (mean 0.075 ng/mL; interquartile range 0.038–0.15 ng/mL). Such a varying AMH threshold
formenopause is a novel and biologically plausible finding. AMHbecame undetectable (0.2 ng/mL)
approximately 5 years before the occurrence of menopause, in line with a previous report.
Conclusions: The conformity of the observed and predicted distributions of AMP supports the hy-
pothesis that decliningpopulation averages ofAMHare associatedwithmenopause,makingAMHan
excellent candidate biomarker forAMPprediction. Further researchwill help establish the accuracy of
AMH levels to predict AMP within individuals. (J Clin Endocrinol Metab 98: 1946–1953, 2013)
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Female reproductive success and the length of a wom-an’s fertile life span are considered to be manifesta-
tions of thedynamicdecline of theprimordial follicle pool.
Although age is considered to be the key determinant of
this decline, in young women it is not a reliable predictor
of the duration of their reproductive life span, with future
menopausal age potentially varying considerably between
women of the same age (1). Therefore, an ever-growing
body of research has aimed to identify biomarkers that
adequately assess the remaining supply of follicles in the
ovaries. Anti-Müllerian hormone (AMH) is such a quan-
titativemarker of ovarian reserve. AMH is secreted by the
cohort of antral follicles up to 8 mm in size (2, 3) and has
been shown to adequately reflect the gradual decline in
follicle numbers associated with increasing age (4). Be-
cause the onset ofmenopause is triggered by exhaustion of
the follicle pool and considering that AMH is a reflection
of the size of the remaining follicle pool, AMH has been
used to predict the age at which a woman will become
postmenopausal in both retrospective and prospective co-
hort studies (5–8). Although the predictive capacity of
AMH in these studies was promising, they were based on
small numbers of women, justifying further confirmation
in larger cohorts.
Several models have been suggested to represent the
age-relatedAMHdecline and the age atwhichmenopause
occurs (7, 9, 10). Of these, a quadratic regression function
of age has emerged as the preferred model (10, 11). How-
ever, new insights into the nature of AMHdecline, such as
the suggestion that AMH becomes undetectable 5 years
prior to the final menstrual period (12), have prompted a
collaboration of efforts to reassess the relationship be-
tween AMH and the onset of menopause, using a previ-
ously described approach (7) but with data from a vastly
larger cohort of women. The aim of the current study was
thus to model age at menopause based on ovarian reserve
status derived from age and AMH and to confirm the
conformity of predicted and observed AMP distributions.
Materials and Methods
Subjects
To investigate age-dependent changes inAMH,we combined
information from different sources into 1 data set for analysis.
AMH and age were obtained from women attending 3 central-
ized AMH testing facilities within the United Kingdom and 1 in
the United States. The UK laboratories were the University of
Glasgow (n 1407) theGlasgowCentre for ReproductiveMed-
icine (GCRM; n  1515), and the Glasgow Royal Infirmary
(GRI; n  6783). These AMH values were measured as part of
the routine fertility work-up and thus represent all women who
would attend these infertility clinics. An additional group of
womenwith normal pelvic ultrasounds and confirmedovulation
but whose partners were known to have severe male factor in-
fertility (5 000 000 sperm/mL) requiring intracytoplasmic
sperm injectionwas also included (GRI, n927) (10).A final set
of 16 931AMHmeasurementswas fromReproSource, a clinical
reference laboratory that provides centralized AMH testing for
US fertility clinics (11). For all women, samples were measured
between July 2006 and October 2009. Due to the centralized
sources of the AMH values, only age and AMH concentration
were known, with no clinical characteristics of the women
available.
The distribution of age at menopause was estimated from
another cohort of women from the Prospect-European Prospec-
tive Investigation into Cancer and Nutrition (Prospect-EPIC).
This cohort consists of 17 357 women aged between 50 and 70
years who were recruited between 1993 and 1997 for a nation-
wide breast cancer screening program conducted in The Neth-
erlands. Menopausal status and past reproductive health were
derived from extensive questionnaires on reproductive history
(13, 14). The World Health Organization definition of meno-
pause, namely the absence of spontaneous menstrual bleeding
for more than 12 months, was used. For the current study, a
cross-sectional cohort of women with a recorded natural meno-
pause was selected from the initial prospective cohort. Only
women aged 58 years and older were selected to avoid under-
representation of women who reached menopause at a late age,
and from these women, only those women with some indication
of subfertility provided data on age atmenopause. Thesewomen
were considered to bemore similar (in all parameters except age)
to those from whom the AMH concentrations were obtained.
Subfertility was assessed via questionnaires and women were
considered to have an indication of subfertility if they had 1 or
more of the following criteria: (1) having had an irregular men-
strual cycle pattern between 30 and 40 years of age, (2) having
consulted a physician for fertility problems, (3) nulliparity, (4)
uniparity, (5) having had amiscarriage, or (6) having a long time
interval between the birth of the first and second child (15). After
application of these selection criteria, 2249 postmenopausal
women could be included in this study.
AMH assay
All four centralized AMH testing facilities used the ELISA
provided by Diagnostic Systems Laboratories (Webster, Texas)
to measure AMH concentrations in batches. Values were deliv-
ered in concentrations of picomoles per liter (conversion factor
topicomoles per liternanogramspermilliliter7.143).At the
University of Glasgow laboratory, the intraassay and interassay
coefficients of variation (CVs) were 6.3% and 11.4%, respec-
tively; at the GCRM laboratory, the CVs were 3.4% and 8.6%,
respectively; at the GRI laboratory, the CVs were 8.6% and
15.4%, respectively; and at the ReproSource laboratory the CVs
were 5% and 8%, respectively (10, 11). The limit of detection of
these AMH assays was set at 0.2 ng/mL (16).
Analysis
Modeling of age-related AMH decline
The data on AMH and age from the 4 different centers were
analyzed using a robust regressionmethodology, with quadratic
functions of age to describe the means (10, 11) and skew-t dis-
tributions to describe the residual variation about these means
(17). [For maximum likelihood estimation (see below), those
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results less than the assay detection limit contribute the infor-
mation AMH  0.2 ng/mL to the likelihood.] A natural loga-
rithmic transformation of AMH was applied to stabilize the re-
sidual variance in AMHconcentrations, thereby creating amore
homogenous distribution, but the residual standard deviation
was allowed to be age dependent as a check on the efficacy of
this transformation. All these assumptions formed amodel for
age-related change in AMH concentrations with 3 compo-
nents: 1) mean of log(AMH)   age  age2; 2) SD
of log(AMH)  exp(    age); and 3) skew-t distribution
of residuals [log(AMH)  mean]/SD.
Predicted and observed age at menopause
Our hypothesis was that variation in age-specific AMH con-
centrations corresponds to variation in the age at which meno-
pause occurs, through the notion of a critical threshold whereby
AMH falling below this threshold represents follicle depletion to
the extent that cycles are no longer sustained and menopause
follows. From the above (regressionbased)model for age-related
change inAMH,probabilities ofAMHat any specified age being
below such a threshold can be calculated and related to age at
menopause through the following equation: probability that
AMH level at age y is below threshold probability that meno-
pause has occurred before or at age y.
In thisway a probability distribution of age atmenopause can
be determined for any given threshold and thus provides amodel
for predicting age at menopause. Recent studies have shown
substantial inter- and intracycle fluctuations in AMH for indi-
vidual women (18–20), which may be affecting the AMH data
but could not be expected to contribute to varying fertility be-
tween women. So to allow for such extraneous variation in
AMH, adifferent SDand skew-t residual distribution from those
in the regression model were used in constructing this predictive
distribution of menopausal age [ie, only the equation for the
mean of log(AMH) from the regression analysis was used here].
These two linked models, for AMH and age at menopause,
were fitted to both data sets (AMH and Prospect-EPIC) by max-
imizing the combined likelihood of all these data. This approach
gave estimates of all parameters used in themodel to describe the
following: the mean (, , and ); SD ( and ); the skew-t re-
sidual distribution for the AMH and age regression model
(above); the critical AMH threshold; and the (different) SD and
skew-t residual distribution used in the construction of the pre-
dictive distribution of menopausal ages. Agreement between the
AMH-based predictive distribution and the observed distribu-
tion of age at menopause was assessed by a visual comparison of
their cumulative frequencies.
Nomogram
Anomogramwas created to show estimated age-specific per-
centiles forAMH(lower5%,10%,and25%;median; andupper
75%, 90%, and 95%) from the fitted (regression) model for
age-related change in AMH, with the corresponding percentiles
of the fitted distribution of menopausal age derived from the
AMH threshold modeling. Individual predictions can be made
from percentiles of themenopausal age distribution correspond-
ing to those inwhichan individualwoman’sAMHconcentration
and age are located in the nomogram. Only women between the
ages of 25and55years are represented in thenomogram; this age
range was chosen because it represents the most clinically rele-
vant group for the prediction of the remaining fertile life. More-
over, previous studies have shown age-based AMH models to
functionpoorly at the extremesof theagedistribution (7, 10,11).
Finally, the estimated distribution of the age at which AMH
drops below the detectable limit of the AMH assay (0.2 ng/mL)
was comparedwith the estimateddistributionof the age atwhich
AMH drops below the critical menopausal threshold to assess
the time span between AMH becoming undetectable and the
predicted onset of menopause.
All data were analyzed usingMATLAB, version 7.2 software
(The MathWorks Inc, Natick, Massachusetts).
Results and Discussion
Results
In the full AMHdata set, there were 3394 womenwith
AMH values less than 0.2 ng/mL and actual values from
24 169 women. This latter group had a mean age of 34.6
years (5.3 years) and mean AMH of 2.5 ng/mL (2.8
ng/mL). In the cohort of thewomenwith any indication of
subfertility in the Prospect-EPIC data set (n  2249), the
mean age was 63.3 years (3.4 years), with a mean age at
the natural menopause of 49.9 years (4.5 years) and a
median 50 years. Table 1 provides the summary statistics
of the different cohorts of subjects.
The mean age-related AMH profiles from individual
regression analyses of data from the 4 different sources are
shown in Supplemental Figure 1, published on The Endo-
crine Society’s Journals Online web site at http://jcem.
endojournals.org. The fitted quadratic regressions of log-
(AMH) on age from the different centers are very similar,
particularly over the age range of 25–55 years, although
Table 1. Summary Statistics of the Different Cohorts of Subjects
GRI GCRM UoG US Prospect-EPIC
n 7710 1515 1407 16 931 2249
Age, y 34.0 (30.0–38.0) 36.8 (32.9–39.8) 34.9 (31.4–37.5) 35.3 (31.0–39.0) 63.0 (60.0–66.0)
AMH, ng/mL 2.07 (0.97–3.74) 1.43 (0.74–2.77) 1.67 (0.80–2.95) 1.60 (0.76–3.15)
AMH measures below
detection, n
729 196 134 2335
Age at menopause, y 50.0 (48.0–53.0)
Abbreviations: UoG, University of Glasgow; US, ReproSource United States. Data are medians (interquartile range) unless otherwise indicated.
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thedifferences between theseprofileswere statistically sig-
nificant (P  .001) due to the large amount of data used.
At the extremes of age, greater discrepancies were appar-
ent, but this can be largely accounted for by the estimated
meansbeing less precise there.Moreover, only0.3%of the
residual SD could be attributed to the differences between
the sources, so these differences were deemed to be of no
practical or clinical significance. There is a clear trend of
decreasing AMHwith increasing age after about 25 years
in all the profiles.
The mean age-related AMH profile from a single re-
gression analysis of the combined data from all 4 sources
plotted with the corresponding 95% confidence intervals
(CIs) and the 90% probability range for observed AMH
values are shown in Supplemental Figure 2. According to
this figure, the mean AMH starts to decline from approx-
imately 20 years of age and continues to decline steadily
until it becomes undetectable. The logarithmic transfor-
mation of AMHhas slightly overcompensated for the het-
erogeneous residual variation of the rawAMHdata as can
be seen from the broadening 90% probability range with
increasing age.
Figure 1 shows the fit of the distributionof age atmeno-
pause predicted byAMH falling below a critical threshold
estimated to be 0.075 ng/mL (with SE 0.004), in which
good agreement can be seenwith the distribution from the
Prospect-EPIC data onwomenwith any indication of sub-
fertility. Shown for comparison is the very poor fit ob-
tained by assuming the same distribution of log(AMH) in
constructing the predictive distribution of menopausal
ages as that from the regression analysis of log(AMH) and
age. In fact, the residual SD from this regression analysis
had to be reduced by multiplying it by an estimated factor
of 0.56 (95% CI 0.51–0.61) to achieve the improved fit
shown in Figure 1; in other words, there was significantly
(P .001) more variation in the AMH levels than would
beneeded to explain the variation in age atmenopause.All
of the model parameter estimates are shown in the online
Supplemental Table 1.
In Figure 2, a nomogram is depicted that describes an
age-related AMH decline for women in terms of the fifth,
10th, 25th, 50th, 75th, 90th, and 95th percentiles of age-
specific AMH concentrations. The estimated critical
AMH threshold (0.075 ng/mL) is also indicated in this
figure. The corresponding percentiles of the predictive dis-
tribution of age at menopause (AMP) are shown adjacent
to these AMH percentile curves in Figure 2; the estimated
fifth, 10th, and 25th AMP percentiles (with SEs in paren-
theses) are 41.9 (0.27) years, 44.4 (0.19) years, and 47.6
(0.12) years, respectively; the estimated 50th AMP per-
centile (or median) is 50.5 (0.09) years, and estimated
75th, 90th, and 95th AMP percentiles are 52.8 (0.08)
years, 54.7 (0.10) years, and 55.8 (0.11) years, respec-
tively. Women with AMH concentrations between per-
centiles can expect menopause to occur between the cor-
responding AMP percentiles; for example, a 40-year-old
womanwith an AMH concentration of 1 ng/mL, which is
just above the 50th AMH percentile and just below the
Figure 1. Predicted vs observed distributions of age at menopause.
The distribution of observed AMP from the Prospect-EPIC cohort of
subfertile women (solid line) is shown compared with 2 predictive
distributions constructed from AMH falling below a critical threshold;
the dotted line shows relatively poor agreement when the residual
distribution of AMH from the regression analysis is used in the
predictive model for AMP, whereas the dashed line shows much better
agreement from using a different distribution of AMH.
Figure 2. AMH nomogram and predictions of age at menopause. The
estimated age-specific 5%, 10%, 25%, 50%, 75%, 90%, and 95%
AMH percentiles from the fitted regression model are plotted. The
corresponding percentiles of AMP modeled by AMH falling below a
critical threshold are shown adjacent to these AMH percentiles. The
critical threshold (0.075 ng/mL) is depicted by the faint solid horizontal
line, whereas the faint dashed horizontal lines indicate the
approximate interquartile range when the threshold is allowed to vary.
A 40-year-old female with an AMH of 1 ng/mL, which is between the
50th and 75th percentiles (denoted by ) would thus be expected to
have an AMP between 50.5 and 52.8 years.
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75th percentile (denoted by  in Figure 2), can expect
menopause just after 50.5 years and below 52.8 years.
Figure 3 shows that the age at which a woman’s AMH
drops below the detection limit of the assay that was used
in this study (0.2 ng/mL) has a distribution that, when
compared with the distribution of the age at which AMH
falls below the critical threshold for menopause, indicates
that menopause occurs approximately 5 years after AMH
becomes undetectable.
Discussion
This studydemonstrates2 important things. First,wehave
shown a close conformity between the distribution of ob-
served age at menopause and a predictive distribution us-
ing a robust regression model of changing AMH with in-
creasing age and the assumption that menopause is
associatedwithAMH falling below a critical threshold (in
which AMH represents follicle depletion to the extent to
which menopause ensues). Second, we have confirmed
earlier reports that AMH becomes undetectable approx-
imately 5 years prior to menopause. The close conformity
of the shape of the observed and AMH-predicted distri-
butions of age at menopause supports the hypothesis that
AMH influences the timing of reproductive milestones
such as menopause. The findings in this study generally
confirm both the dynamics of age-related AMHdecline as
well as the possibility of prediction of age atmenopause as
demonstrated inprevious studies (7, 10, 11). Both findings
will have impact on research lines in which prospective
data are nowbeing obtained to demonstrate the claim that
AMHat a young age could be a forecaster of reproductive
life span.
The estimated AMH threshold after which menopause
occurs was 0.075 ng/mL, slightly lower than the value
(0.086 ng/mL) given by van Disseldorp et al in 2008 (7),
which was based on a much smaller data set of proven
fertile women with only a fraction (0.5%) of the AMH
values used in this study and is consequently a much less
precise estimate, and in any case differentmenopausal age
data were used. Unfortunately, it would not be possible to
confirm this threshold in any prospective study because
the AMH assay applied in this study is not considered to
be accurate below a detection limit of 0.2 ng/mL (16, 21,
22). Nevertheless, because it is not uncommon to find 1 or
2 antral follicles by ultrasound in postmenopausal
women, this threshold seems plausible.
The finding from our modeling, that the age at which
AMH falls below the critical threshold for menopause
tends to be about 5 years after the age at which AMH
drops below the detection limit of the assay, is in concor-
dance with Sowers et al (12), who showed that AMH
values decline to or past the detection limit at approxi-
mately 5 years before the final menstrual period.
In achieving the good fit to the Prospect-EPIC data on
menopausal ages, it was necessary to reduce the SD of
log(AMH) used in constructing the AMH-based predic-
tive distribution by multiplying the residual SD from the
regression model of log(AMH) and age by an estimated
0.56 (95% CI 0.51–0.61). Some excess AMH variation
will be due to the inter- and intracycle variation within
women, and van Disseldorp et al (18) have shown that
11% of the (age adjusted) AMH variance could be due to
the intercycle variation and 13% due to the intracycle
variation for individual women. If these 2 sources of the
extraneous AMH variation were independent, then 76%
of the overall AMHvariance (or 87%of the SD)would be
due to the variation between women; but if these sources
were positively correlated, then the variation between
women could be as low as 52% (corresponding to max-
imal correlation) of the overall AMHvariance (or 72%of
the SD). This figure of 0.72 is outside the above 95% CI
for the estimated factor by which the AMH residual SD
was reduced to achieve a good fit of the predictive distri-
bution of menopausal age. This means that the inter- and
intracycle AMH variation within women cannot explain
all of the excess variation in AMH apparent from the re-
gression analysis, and a significant amount remains.
The effect of any excess AMHvariation can be reduced
by allowing the critical AMH threshold for menopause to
vary between women in such a way that it is positively
correlated with their actual AMH concentration: higher
for women with high AMH for their age and lower for
Figure 3. Comparison of the distributions of age at which the AMH
threshold and AMH assay detection limit are reached. The estimated
distribution of the age at which AMH drops below the detection limit
(dashed line) showing that this occurs about 5 years before AMH drops
below the critical threshold for menopause (solid line).
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womenwith lowAMH for their age, thereby reducing the
variation of the AMH-predicted age at menopause. Using
the above figure of 72% of the AMH residual SD in the
determinationof the predicteddistributionofmenopausal
ages leads to an approximate estimate of the interquartile
range of the necessary threshold variation of 0.038–0.15
ng/mL. This is indicated in Figure 2 with the previous
(constant) threshold estimate (0.075 ng/mL) now being
the mean. Thresholds within this interquartile range
would be more likely for women with AMH concentra-
tions between the corresponding (25th and 75th) AMH
percentiles than for women with AMH outside these per-
centiles who would be more likely to have more extreme
threshold values.
This discrepancy between variation in age at meno-
pause and residual variation in AMH may not be an ar-
tifact ofAMH, for a similardiscrepancybetweenvariation
in age atmenopause and residual variation in nongrowing
follicles is apparent in the study by Wallace and Kelsey
(23) inwhich themenopausal age predictionwas based on
follicle numbers falling below a critical level of 1000: in
that study the 95% prediction interval was 39–60 years
compared with the observed 40–57 years from the Pros-
pect-EPIC data from women with and without any indi-
cation of subfertility. Perhaps it can be reasoned as fol-
lows: if womenwith a higher-than-averageAMHfor their
age are predestined to have a higher age at menopause,
then this would result in an increased time frame for other
determinants of the ovarian aging process to play a role,
thus resulting in menopause occurring despite still having
some follicles left in the ovaries. The supposed determi-
nants may be somatic or ovarian factors that prevent ovu-
lation and cycling at near, but not complete, depletion of
the follicle pool. Alternatively, a compensatory mecha-
nism may exist whereby prematurely aged ovaries (as ex-
pressed by lower than average age specific AMH levels)
have a decreased threshold for menopause as a means of
extending reproductive life. Evidence for such a varying
threshold can be gleaned from recent studies inwhich data
show that some women are regularly cycling despite their
AMH concentrations being clearly below the detection
limit and very close to zero (19, 24). Furthermore, a study
in 50 postmenopausal women revealed that 36% of
women still had an AMH above the assay’s limit of de-
tection at their final menstrual period, whereas 64%were
below it (12).
There also may be other sources of extraneous AMH
variation that could reduce the need for a varying thresh-
old. Some extraneous AMH variation in this study would
be from the different sources of the data, but this only
amounted to a negligible 0.3%of the residual SD. It could
be argued that the excess variation in AMH may be ex-
plained simply by characteristics of the cohort. Because
the AMH values are measured in women attending an
infertility clinic, one can expect the cohort to include
women with either polycystic ovary syndrome (high age
specific AMH) or premature ovarian insufficiency (low
age specific AMH), which could contribute to excess vari-
ation in AMH (25, 26). Extra variation in AMH may be
due to lifestyle factors like smoking, which has been as-
sociated with a decrease in age-specific AMH and an ear-
lier age at menopause (27–29). Assuming similarity be-
tween the AMH cohort and the Prospect-EPIC cohort, it
is, however, likely that the level of occurrence of such
determinants of AMH would also be similar, and hence,
their effects on AMH-predicted age at menopause might
be expected to be similar.
The major strength of this study is that it provides the
largest body of information in which the association be-
tween AMH and age at menopause has ever been tested.
There are, however, some limitations; for example, data
on age at menopause were based on self-reporting, which
may be prone to recall bias. However, several studies have
demonstrated that both the validity and reproducibility of
self-reported age at menopause are good (30, 31). And
from the cohorts of women from whom AMH was mea-
sured, only age andAMHis known; other determinants of
age at menopause such as genetic factors, lifestyle factors,
and reproductive history could not be compared between
this sample of women and the Prospect-EPIC sample (32).
A varying AMH threshold might be seen as a bit of a
drawback in the model for age at menopause in that al-
though it results in a better-fitting model, it cannot be
knownwith any certainty for an individual atwhat thresh-
old AMH would be predictive of menopause. Some un-
certainty in predictions is already apparent according to
a prospective study that showed large and overlapping
95% confidence intervals for the predicted ages at
menopause (5).
Although the findings of the current study support the
notion that AMH does reflect female reproductive status,
applying this to get clinically useful information for indi-
vidual women remains problematic. First, the AMHassay
is no longer widely used because it has been replaced by a
newer AMH GEN II assay (Beckman Coulter, Sinsheim,
Germany). AMH concentrations measured with the GEN
IIassaygivehighervalues than theELISAused in this study
(10, 11). Although consistent correlations have been
found between the newer AMH GEN II assay and the
Diagnostic Systems Laboratory assay (21, 33), the results
shown here should be interpreted as conceptual evidence
that prediction of age at menopause from declining AMH
is possible, rather than used for counseling of individual
patients. Further research on the relationship between
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AMHand age atmenopausewould benefit from using the
newer assay.
Using average AMH concentrations over several cycles
and phases of these cycles would reduce the effect of nat-
ural fluctuations between and within cycles; for example,
averaging 4 measurements could reduce the SD of these
effects by 50%. Additional evidence still needs to be ob-
tained from long-term follow-up studies in which the oc-
currence of menopause is prospectively assessed and
women are subjected to multiple measurements of AMH
over several cycles spaced over a period of 1 or 2 decades.
Four prospective studies exist that provide evidence that
AMH can be used to make more individualized predic-
tions of age at menopause. However, either the follow-up
time was not very long, resulting in few women reaching
menopause, or the included women were of late repro-
ductive agewhen theAMHwasdetermined. Furthermore,
in 3of the studies,AMHwasmeasuredonly once, thus not
permitting the analysis of natural variation within the in-
dividual (5, 6, 8). In the other study, the prediction was
basedon estimating the rate of change inAMH,but it took
3.5 years to get a reliable estimate, and thus 3.5 years
before a prediction could be made (6).
Menopause is the only noticeablemarking point for the
massive, gradual decline in ovarian follicle numbers over
the first 5decades of a female’s life. It canbe seenas the end
of the reproductive life span in women. Age at menopause
shows considerable variation between 40 and 60 years,
with approximately 10% of women becoming meno-
pausal before the age of 45 years. A relationship between
age atmenopause and the endofnatural fertility is thought
to be present, with an interval of approximately 10 years
(34). Therefore, from the prediction of age at menopause,
similar predictions of age at the end of natural fertility can
be extrapolated.
In conclusion, this study shows that AMH levels have
an association with reproductive events such as age at
menopause and reinforces the notion thatAMHis capable
of predicting the timing of such eventsmore informatively
than chronological age alone.
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